New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 17, 2013
09:45 EDTABT, ABT, THOR, THOR, TFX, TFX, SYK, SYK, STJ, STJ, NUVA, NUVA, MDT, MDT, HTWR, HTWR, HSP, HSP, EW, EW, COV, COV, CFN, CFN, BDX, BDX, BSX, BSX, BCR, BCR, BAX, BAX, ZMH, ZMHBarclays' U.S. medical suppplies & devices analysts hold a conference call
U.S. Medical Supplies & Devices Research Team discuss key potential catalysts and top ideas for 2013 on an Analyst/Industry conference call. Relevant covered companies ABT, BAX, BCR, BSX, BDX, CFN, COV, EW, HSP, HTWR, MDT, NUVA, STJ, SYK, TFX, THOR and ZMH will be discussed on the Analyst/Industry conference call to be held January 17 at 10 am.
News For ABT;BAX;BCR;BSX;BDX;CFN;COV;EW;HSP;HTWR;MDT;NUVA;STJ;SYK;TFX;THOR;ZMH From The Last 14 Days
Check below for free stories on ABT;BAX;BCR;BSX;BDX;CFN;COV;EW;HSP;HTWR;MDT;NUVA;STJ;SYK;TFX;THOR;ZMH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 8, 2014
07:26 EDTSTJ, BSXMorgan Stanley to hold a conference
Subscribe for More Information
07:04 EDTBSXBoston Scientific sell-off overdone, says RBC Capital
RBC Capital said the sell-off in Boston Scientific is overdone and that upcoming catalysts will reverse sentiment. The firm would be aggressive buyers ahead of the October 8 FDA Watchman panel and the release of pivotal Synergy data on November 19 AHA meeting. Shares are Outperform rated with a $15 price target.
07:03 EDTTFXTeleflex announces restated indications for ARROW EZ-IO use
Teleflex announced FDA 510 clearance for restated Indications for Use of the Arrow EZ-IO Vascular Access System. The EZ-IO Vascular Access System is now indicated to include the distal femur for pediatric patients.
05:47 EDTBAXBaxter price target raised to $96 from $85 at Piper Jaffray
Subscribe for More Information
September 5, 2014
11:47 EDTCOVOptions with increasing implied volatility
Subscribe for More Information
09:03 EDTTFXTeleflex announces publication of ARROW PICC study
Subscribe for More Information
06:11 EDTMDTMedtronic Linq device being underappreciated, says Citigroup
Citigroup believes the Street is underestimating the near-term potential of Medtronic's recently released Reveal Linq insertable cardiac monitor. Citi thinks the combination of the U.S. Corevalve rollout and Linq contribution will drive sales to the high end of the company's 3%-5% guidance. The firm raised its price target for shares to $74 from $73 and keeps a Buy rating on the stock.
05:46 EDTABTDexCom competition closer after Abbott approval, says Piper Jaffray
Subscribe for More Information
September 4, 2014
13:12 EDTHSPFDA posts approval of Hospira's Milrinone Lactate
Reference Link
10:01 EDTTHORThoratec management to meet with Oppenheimer
Subscribe for More Information
07:17 EDTCFNCareFusion management to meet with Deutsche Bank
Subscribe for More Information
September 3, 2014
11:54 EDTHSPHospira talks to acquire Danone nutrition unit stall, Reuters reports
Subscribe for More Information
11:36 EDTHSPHospira talks to acquire Danone nutrition unit stall, Reuters reports
09:32 EDTABTAbbott receives CE Mark for FreeStyle Libre
Subscribe for More Information
09:03 EDTEWNovation enters heart valve agreement with Edwards Lifesciences
Novation and Edwards Lifesciences announced they have entered into a three-year, sole-source strategic relationship that provides the world's market leading heart valve therapies to the more than 100,000 members and affiliates of VHA, UHC, Children's Hospital Association and Provista. The new agreement with Edwards for its heart valve product portfolio enables Novation to enter the heart valve category for the first time, and expands on the previous relationship between the companies for critical care technologies.
07:10 EDTMDTMedtronic announces CE Mark for CoreValve Evolut R System
Medtronic announced CE Mark for the 23 mm CoreValve Evolut R System for transcatheter aortic valve implantation, or TAVI. The novel, self-expanding valve and 14FR equivalent delivery system offers new capabilities that advance valve performance and deliverability during the procedure, while providing the option to recapture and reposition the valve during deployment phase, if needed.The novel system consisting of the CoreValve Evolut R transcatheter aortic valve and the EnVeo(TM) R Delivery Catheter System is designed for first-time positioning accuracy and also offers a new InLine Sheath that significantly reduces the profile to the lowest on the market; a smaller profile size is believed to minimize the risk of major vascular complications. The new valve is anatomically designed to increase conformability at the annulus for optimal annular fit and sealing, while maintaining supra-annular valve position for improved hemodynamic performance.
September 2, 2014
09:57 EDTSTJSt. Jude Medical announces primary outcome two-year data from FAME 2 trial
Subscribe for More Information
08:07 EDTBSXBoston Scientific closed agreement to acquire Interventional business of Bayer
Boston Scientific (BSX) closed on its previously announced agreement to purchase the Interventional business of Bayer (BAYRY). The addition of the Bayer Interventional strong commercial organization and innovative technologies supports the Boston Scientific strategy to provide a comprehensive portfolio of solutions to treat peripheral vascular disease. The transaction includes the leading AngioJet Thrombectomy System and the Fetch 2 Aspiration Catheter, which are used in endovascular procedures to remove blood clots from blocked arteries and veins, and the JetStream Atherectomy System, used in an innovative and fast-growing therapy to remove plaque and thrombi from diseased arteries.
06:36 EDTMDTMedtronic, AbbVie reimburse executives for inversion-triggered taxes, WSJ says
Subscribe for More Information
September 1, 2014
15:59 EDTSTJSt. Jude Medical announces new Fractional Flow Reserve trial
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use